Cytonics' CYT-108 Shows Favorable Safety Profile in Phase 1 Osteoarthritis Trial
• Cytonics Corporation announced the successful completion of its Phase 1 clinical trial for CYT-108 in nine osteoarthritis patients, with follow-up extending to Day 180.
• The Phase 1 study is a multi-center, randomized, double-blind trial designed to evaluate the safety, pharmacokinetics, and exploratory efficacy of CYT-108 in patients with primary osteoarthritis of the knee.
• CYT-108 is a recombinant variant of alpha-2-macroglobulin (A2M), engineered to enhance its affinity for proteases involved in osteoarthritis, potentially modifying the disease.
• No drug-related adverse events were reported, highlighting CYT-108's potential as a safe and well-tolerated disease-modifying therapy for osteoarthritis.
Cytonics Completes Enrollment in Phase 1 Trial of CYT-108 for Knee Osteoarthritis
• Cytonics has completed enrollment for its Phase 1 clinical trial of CYT-108, a novel recombinant protease inhibitor for osteoarthritis (OA).
• The trial is a multi-center, double-blind, randomized controlled trial (RCT) evaluating the safety and efficacy of CYT-108 in patients with mild-to-moderate knee OA.
• CYT-108 is designed as a disease-modifying therapy, differentiating itself through highly specific and broad-spectrum protease inhibition activity.
• Top-line results from the Phase 1 study are expected in the second quarter of 2025, with plans to file an IND with the FDA.
© Copyright 2025. All Rights Reserved by MedPath